Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Melior Pharmaceuticals
Exton, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Melior has reported Phase 2b completion for tolimidone in Type 2 diabetes (showing favorable clinical safety and progress in efficacy endpoints); an additional Phase 2 program in NASH and ongoing exploratory and out-licensing activities for Type 1 diabetes, plus preclinical and clinical progress for mesocarb in CNS indications.
- Therapeutic areas
- GastroenterologyNeurologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Adhera Therapeutics (tolimidone licensing, Type 1 diabetes)Melior Discovery (drug-repositioning platform access)
Beyond the preview
Go deeper on Melior Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melior Pharmaceuticals.